NADA Number: 141-285 | |
| Proprietary Name |
Convenia® |
|---|---|
| Sponsor |
Pfizer, Inc. |
| Sponsor Address |
235 East 42d St. New York, NY 10017 USA |
| Ingredients |
Cefovecin sodium |
| Species |
Cat, no use class stated or implied Dog, no use class stated or implied |
| Routes of Administration |
Subcutaneous |
| Dose Form |
Liquid (solution) |
| Drug Form |
Powder |
| Dispensing Status |
RX |
| Patent Number |
6020329 |
| Exclusivity |
Newly approved antibiotic, Cefovecin sodium. |
| Withdrawal Time |
Withdrawal times do not apply to the species listed for this product. |
|
Dosage Amount, Indications & Limitations |
522.311 Cefovecin. Specifications: Each milliliter of constituted solution contains 80 milligrams (mg) cefovecin as the sodium salt. Conditions of use: Dogs Amount: Administer 3.6 mg/pound (lb) (8 mg/kilograms(kg)) body weight as a single subcutaneous injection. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete. Indications for use: For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G). Cats Amount: Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection. Indications for use: For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida. Special considerations: Federal law restricts this drug to use by or on the order of a licensed veterinarian. |